These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis. Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G Front Immunol; 2024; 15():1416133. PubMed ID: 38911847 [TBL] [Abstract][Full Text] [Related]
4. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis. Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793 [TBL] [Abstract][Full Text] [Related]
5. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke. Vogelgesang A; Domanska G; Ruhnau J; Dressel A; Kirsch M; Schulze J Stroke; 2019 May; 50(5):1224-1231. PubMed ID: 31009359 [TBL] [Abstract][Full Text] [Related]
6. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase. Hao W; Luo Q; Menger MD; Fassbender K; Liu Y Front Immunol; 2021; 12():792465. PubMed ID: 34975892 [TBL] [Abstract][Full Text] [Related]
7. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis. Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692 [TBL] [Abstract][Full Text] [Related]
8. Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia. Fang M; Yamasaki R; Li G; Masaki K; Yamaguchi H; Fujita A; Isobe N; Kira JI Front Immunol; 2018; 9():2588. PubMed ID: 30464764 [TBL] [Abstract][Full Text] [Related]
10. Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment. Hu S; Hu Y; Tan Z; Zhou C; Zhang C; Yin S; Chen X; Chen K; Wang L; Chen L Eur J Pharmacol; 2024 Jul; 974():176630. PubMed ID: 38692426 [TBL] [Abstract][Full Text] [Related]
11. Siponimod in the treatment of multiple sclerosis. Goodman AD; Anadani N; Gerwitz L Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362 [No Abstract] [Full Text] [Related]
12. Experimental Autoimmune Encephalomyelitis (EAE)-Induced Elevated Expression of the E1 Isoform of Methyl CpG Binding Protein 2 (MeCP2E1): Implications in Multiple Sclerosis (MS)-Induced Neurological Disability and Associated Myelin Damage. Khorshid Ahmad T; Zhou T; AlTaweel K; Cortes C; Lillico R; Lakowski TM; Gozda K; Namaka MP Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28604632 [TBL] [Abstract][Full Text] [Related]
13. Does Siponimod Exert Direct Effects in the Central Nervous System? Kipp M Cells; 2020 Jul; 9(8):. PubMed ID: 32722245 [TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. McGinley MP; Cohen JA Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020 [TBL] [Abstract][Full Text] [Related]
15. Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis. Hu ZL; Luo C; Hurtado PR; Li H; Wang S; Hu B; Xu JM; Liu Y; Feng SQ; Hurtado-Perez E; Chen K; Zhou XF; Li CQ; Dai RP Theranostics; 2021; 11(2):715-730. PubMed ID: 33391501 [No Abstract] [Full Text] [Related]
17. VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage. Abad C; Jayaram B; Becquet L; Wang Y; O'Dorisio MS; Waschek JA; Tan YV J Neuroinflammation; 2016 Jun; 13(1):169. PubMed ID: 27357191 [TBL] [Abstract][Full Text] [Related]
18. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses. Feng M; Shu Y; Yang Y; Zheng X; Li R; Wang Y; Dai Y; Qiu W; Lu Z; Hu X Neurochem Int; 2014 Jan; 64():64-72. PubMed ID: 24274996 [TBL] [Abstract][Full Text] [Related]
19. Preventing the BDNF and NGF loss involved in the effects of cornel iridoid glycoside on attenuation of experimental autoimmune encephalomyelitis in mice. Qu Z; Zheng N; Zhang Y; Zhang L; Liu J; Wang Q; Yin L Neurol Res; 2016 Sep; 38(9):831-7. PubMed ID: 27373350 [TBL] [Abstract][Full Text] [Related]